Iron Chelators: Dosing and Monitoring
All three iron chelators—deferoxamine, deferasirox, and deferiprone—are FDA-approved and effective for managing transfusional iron overload, with specific dosing regimens and monitoring requirements that must be strictly followed to prevent life-threatening complications. 1
Deferoxamine (Desferrioxamine)
Dosing Regimen
- Chronic dosing: 20-50 mg/kg/day 1
- Route: Subcutaneous via portable pump (IV for heart failure/intensive chelation) 1
- Frequency: 8-14 hour infusion, 5-7 days per week 1
- Preparation: 10% solution administered subcutaneously 1
- Intensive chelation: Continuous IV infusion when rapid iron removal needed 1, 2
Monitoring Requirements
- Ophthalmologic examinations (risk of visual disturbance) 1
- Audiological testing (risk of sensorineural deafness) 1
- Growth monitoring in pediatric patients 1
- Renal function (risk of renal toxicity, especially with high IV doses) 1
- Infection surveillance for Yersinia and Klebsiella 1
Key Adverse Effects
Primary concerns include sensorineural deafness, visual disturbances, skeletal abnormalities, and growth retardation—particularly when doses are excessive relative to iron burden 1. Local infusion-site reactions (induration, erythema, swelling, itch) are most common 1.
Deferiprone
Dosing Regimen
- Chronic dosing: 75-100 mg/kg/day 1
- Route: Oral 1
- Frequency: Three times daily (due to 1.5-2.5 hour half-life) 1
- Timing: Peak levels at 45-60 minutes fasted, up to 2 hours if fed 1
Critical Monitoring Requirements
- Weekly absolute neutrophil count (ANC) to detect agranulocytosis early 1
- Immediate drug discontinuation if ANC <0.5×10⁹/L 1
- Temporary hold for neutropenia (ANC 0.5-1.5×10⁹/L) 1
- Liver enzymes (transient elevations common) 1
- Joint examination for arthropathy 1
- Zinc levels (deficiency reported in minority) 1
Key Adverse Effects
Agranulocytosis is the most serious adverse effect, occurring in approximately 1% of patients (0.6 cases per 100 patient-years) 1. Patients must immediately report fever, sore throat, or flu-like symptoms 1. Gastrointestinal symptoms (nausea, vomiting, abdominal pain) and arthropathy are common but usually manageable 1.
Deferasirox
Dosing Regimen
- Chronic dosing: 20-40 mg/kg/day 1
- Route: Oral (dispersible tablets) 1
- Frequency: Once daily (8-16 hour half-life supports 24-hour coverage) 1
- Administration: Dissolve in water or juice, give at least 30 minutes before meals 1
Monitoring Requirements
- Serum creatinine at baseline and regularly (mild elevations in ~33% of patients) 1
- Creatinine clearance (contraindicated if <40 mL/min or creatinine >2× age-appropriate normal) 1
- Liver function tests (ALT elevations common) 1
- Renal function tests (risk of Fanconi syndrome with overdosage) 1
- Audiological and ocular testing (~1% incidence of toxicity) 1
Key Adverse Effects
Mild-to-moderate gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), diffuse maculopapular skin rash, and increased ALT and creatinine are most common 1. These rarely require discontinuation and often resolve spontaneously or with dose adjustment 1.
Excretion Patterns (Critical for Understanding Monitoring)
Common Pitfalls to Avoid
Dose-to-iron-burden mismatch: Serious adverse events occur particularly when chelator doses are excessive relative to actual iron burden 1. Always adjust doses based on ferritin trends and organ iron assessments.
Inadequate neutrophil monitoring with deferiprone: Weekly ANC monitoring is non-negotiable—agranulocytosis can develop rapidly and is potentially fatal if not caught early 1.
Ignoring renal function with deferasirox: The drug is contraindicated in significant renal impairment, and Fanconi syndrome cases have been reported with overdosage relative to iron burden 1.
Poor adherence with deferoxamine: The cumbersome parenteral administration significantly affects compliance 1. Consider switching to oral agents if adherence is problematic.
Efficacy Monitoring for All Chelators
- Serum ferritin levels at regular intervals 1
- Cardiac T2 MRI* (improves over months with effective chelation) 1, 2
- Liver iron content assessment 1
- Left ventricular ejection fraction (can improve substantially within weeks in cardiac iron overload) 1, 2
The choice among these three chelators depends on patient-specific factors including renal function, compliance capability, iron burden severity, and individual tolerance profiles 3. In heart failure or severe cardiac iron overload (T2* <6 ms), continuous IV deferoxamine or combination therapy may be necessary 1.